| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 16 | 2022 | 158 | 5.690 |
Why?
|
| Heart Transplantation | 14 | 2023 | 180 | 3.130 |
Why?
|
| Thoracic Surgery | 8 | 2021 | 80 | 3.070 |
Why?
|
| Bioprosthesis | 5 | 2021 | 38 | 2.720 |
Why?
|
| Heart Failure | 11 | 2022 | 966 | 2.370 |
Why?
|
| Aortic Aneurysm | 5 | 2018 | 81 | 2.260 |
Why?
|
| Prosthesis-Related Infections | 5 | 2017 | 34 | 2.090 |
Why?
|
| Coronary Artery Bypass | 8 | 2021 | 292 | 2.020 |
Why?
|
| Heart Valve Prosthesis | 4 | 2021 | 107 | 1.960 |
Why?
|
| Heart Ventricles | 7 | 2021 | 267 | 1.750 |
Why?
|
| Societies, Medical | 6 | 2015 | 401 | 1.680 |
Why?
|
| Coronary Artery Disease | 8 | 2021 | 326 | 1.590 |
Why?
|
| Aortic Valve Insufficiency | 4 | 2020 | 42 | 1.580 |
Why?
|
| Heart Valve Diseases | 4 | 2021 | 94 | 1.540 |
Why?
|
| Humans | 93 | 2026 | 65826 | 1.530 |
Why?
|
| Aortic Valve | 9 | 2021 | 181 | 1.510 |
Why?
|
| Myocardial Infarction | 9 | 2021 | 921 | 1.500 |
Why?
|
| Thoracic Surgical Procedures | 4 | 2015 | 42 | 1.450 |
Why?
|
| Cardiac Surgical Procedures | 6 | 2026 | 272 | 1.410 |
Why?
|
| Operating Rooms | 2 | 2021 | 60 | 1.330 |
Why?
|
| Myocardium | 9 | 2017 | 302 | 1.310 |
Why?
|
| Marfan Syndrome | 2 | 2020 | 19 | 1.280 |
Why?
|
| Mitral Valve | 4 | 2019 | 126 | 1.260 |
Why?
|
| Heart | 7 | 2021 | 298 | 1.230 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2021 | 171 | 1.170 |
Why?
|
| Aorta | 7 | 2021 | 108 | 1.150 |
Why?
|
| Endothelial Progenitor Cells | 2 | 2018 | 10 | 1.080 |
Why?
|
| Aortic Aneurysm, Thoracic | 3 | 2019 | 109 | 1.060 |
Why?
|
| Chlorhexidine | 2 | 2018 | 17 | 1.050 |
Why?
|
| Heart Neoplasms | 2 | 2021 | 36 | 1.040 |
Why?
|
| Jehovah's Witnesses | 2 | 2019 | 19 | 1.030 |
Why?
|
| Cardiomyopathies | 3 | 2017 | 137 | 0.960 |
Why?
|
| Aortic Diseases | 2 | 2018 | 65 | 0.960 |
Why?
|
| Aorta, Thoracic | 4 | 2020 | 80 | 0.940 |
Why?
|
| Treatment Outcome | 20 | 2022 | 5830 | 0.940 |
Why?
|
| Blood Vessel Prosthesis Implantation | 4 | 2018 | 277 | 0.940 |
Why?
|
| Debridement | 5 | 2017 | 35 | 0.900 |
Why?
|
| Vascular Surgical Procedures | 4 | 2018 | 240 | 0.880 |
Why?
|
| Reoperation | 6 | 2018 | 307 | 0.870 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2022 | 66 | 0.870 |
Why?
|
| Internship and Residency | 3 | 2021 | 802 | 0.840 |
Why?
|
| Shock, Cardiogenic | 5 | 2022 | 108 | 0.820 |
Why?
|
| Surgical Procedures, Operative | 2 | 2021 | 145 | 0.730 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2021 | 42 | 0.720 |
Why?
|
| Thymus Neoplasms | 1 | 2021 | 24 | 0.700 |
Why?
|
| Mediastinal Neoplasms | 1 | 2021 | 21 | 0.700 |
Why?
|
| Sarcoma | 1 | 2021 | 36 | 0.690 |
Why?
|
| Saphenous Vein | 1 | 2022 | 51 | 0.690 |
Why?
|
| Extracorporeal Circulation | 1 | 2021 | 6 | 0.680 |
Why?
|
| Coronary Stenosis | 5 | 2015 | 41 | 0.670 |
Why?
|
| Food Hypersensitivity | 1 | 2021 | 26 | 0.660 |
Why?
|
| Ventricular Function, Right | 2 | 2018 | 28 | 0.660 |
Why?
|
| Cardioplegic Solutions | 1 | 2020 | 9 | 0.650 |
Why?
|
| Tissue and Organ Procurement | 1 | 2021 | 40 | 0.650 |
Why?
|
| Heart Arrest, Induced | 1 | 2020 | 13 | 0.650 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2020 | 6 | 0.650 |
Why?
|
| Loeys-Dietz Syndrome | 1 | 2020 | 5 | 0.640 |
Why?
|
| Coronary Vessels | 6 | 2017 | 125 | 0.640 |
Why?
|
| Endovascular Procedures | 2 | 2019 | 633 | 0.640 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 2022 | 19 | 0.640 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2020 | 23 | 0.630 |
Why?
|
| Extracellular Vesicles | 1 | 2020 | 47 | 0.620 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2022 | 235 | 0.610 |
Why?
|
| Myocardial Revascularization | 1 | 2020 | 78 | 0.610 |
Why?
|
| Calcinosis | 2 | 2018 | 84 | 0.600 |
Why?
|
| Reperfusion Injury | 3 | 2017 | 58 | 0.600 |
Why?
|
| Male | 36 | 2018 | 31398 | 0.570 |
Why?
|
| Leadership | 1 | 2021 | 214 | 0.560 |
Why?
|
| Foreign-Body Migration | 2 | 2016 | 24 | 0.560 |
Why?
|
| Dental Porcelain | 1 | 2018 | 3 | 0.550 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2019 | 98 | 0.550 |
Why?
|
| Pulmonary Artery | 2 | 2018 | 96 | 0.540 |
Why?
|
| Anaphylaxis | 1 | 2018 | 41 | 0.530 |
Why?
|
| Prosthesis Implantation | 1 | 2017 | 30 | 0.530 |
Why?
|
| Myocardial Ischemia | 5 | 2005 | 121 | 0.520 |
Why?
|
| History, 20th Century | 6 | 2015 | 234 | 0.520 |
Why?
|
| Intraoperative Complications | 1 | 2018 | 88 | 0.520 |
Why?
|
| Stroke | 3 | 2017 | 1225 | 0.520 |
Why?
|
| Spinal Cord Ischemia | 1 | 2017 | 15 | 0.520 |
Why?
|
| Hypertension, Pulmonary | 1 | 2018 | 100 | 0.510 |
Why?
|
| Mycobacterium Infections | 1 | 2017 | 15 | 0.510 |
Why?
|
| Anticoagulants | 2 | 2026 | 529 | 0.510 |
Why?
|
| Middle Aged | 19 | 2018 | 18491 | 0.500 |
Why?
|
| Mycobacterium | 1 | 2017 | 37 | 0.500 |
Why?
|
| Laparoscopy | 1 | 2021 | 492 | 0.500 |
Why?
|
| Education, Medical, Graduate | 3 | 2021 | 348 | 0.500 |
Why?
|
| Drug Tolerance | 1 | 2017 | 33 | 0.500 |
Why?
|
| Tissue Donors | 3 | 2023 | 147 | 0.500 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2017 | 29 | 0.500 |
Why?
|
| Spouses | 1 | 2017 | 40 | 0.490 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2018 | 160 | 0.480 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2017 | 118 | 0.480 |
Why?
|
| Bone Marrow | 1 | 2017 | 178 | 0.480 |
Why?
|
| Mitral Valve Prolapse | 1 | 2016 | 11 | 0.480 |
Why?
|
| Endothelial Cells | 1 | 2018 | 216 | 0.470 |
Why?
|
| Empathy | 1 | 2017 | 69 | 0.470 |
Why?
|
| Sternum | 1 | 2016 | 29 | 0.470 |
Why?
|
| Aged | 17 | 2017 | 15141 | 0.470 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2015 | 13 | 0.470 |
Why?
|
| Hypothermia, Induced | 1 | 2016 | 48 | 0.470 |
Why?
|
| Critical Illness | 1 | 2019 | 342 | 0.470 |
Why?
|
| Hematuria | 1 | 2016 | 23 | 0.460 |
Why?
|
| Staphylococcal Infections | 2 | 2017 | 131 | 0.460 |
Why?
|
| Early Medical Intervention | 1 | 2015 | 20 | 0.450 |
Why?
|
| Religion and Medicine | 1 | 2015 | 20 | 0.450 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2005 | 23 | 0.450 |
Why?
|
| Surgical Wound Infection | 2 | 2016 | 126 | 0.450 |
Why?
|
| Watchful Waiting | 1 | 2015 | 33 | 0.450 |
Why?
|
| Caspase Inhibitors | 2 | 2005 | 24 | 0.450 |
Why?
|
| Aortic Rupture | 1 | 2015 | 47 | 0.450 |
Why?
|
| Models, Anatomic | 2 | 2012 | 63 | 0.450 |
Why?
|
| Models, Cardiovascular | 3 | 2012 | 84 | 0.440 |
Why?
|
| Consensus | 1 | 2016 | 174 | 0.430 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2015 | 48 | 0.430 |
Why?
|
| Oligopeptides | 2 | 2005 | 135 | 0.430 |
Why?
|
| Tachycardia, Ventricular | 1 | 2016 | 131 | 0.430 |
Why?
|
| Ventricular Remodeling | 2 | 2013 | 95 | 0.420 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2014 | 38 | 0.420 |
Why?
|
| Graft Rejection | 6 | 2007 | 304 | 0.410 |
Why?
|
| Central Venous Catheters | 1 | 2014 | 17 | 0.400 |
Why?
|
| Carotid Stenosis | 1 | 2015 | 100 | 0.400 |
Why?
|
| Female | 23 | 2017 | 34414 | 0.400 |
Why?
|
| Heart Arrest | 1 | 2016 | 177 | 0.400 |
Why?
|
| Iatrogenic Disease | 1 | 2014 | 58 | 0.400 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2013 | 170 | 0.390 |
Why?
|
| Caregivers | 1 | 2017 | 298 | 0.390 |
Why?
|
| Heart Atria | 4 | 2019 | 137 | 0.390 |
Why?
|
| Catheterization, Central Venous | 1 | 2014 | 84 | 0.390 |
Why?
|
| Heart Failure, Systolic | 1 | 2013 | 16 | 0.380 |
Why?
|
| Dependovirus | 1 | 2019 | 760 | 0.370 |
Why?
|
| Transcriptome | 1 | 2016 | 408 | 0.370 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 876 | 0.370 |
Why?
|
| Liposarcoma | 1 | 2012 | 8 | 0.360 |
Why?
|
| Genetic Therapy | 2 | 2019 | 852 | 0.360 |
Why?
|
| Aortic Valve Stenosis | 1 | 2015 | 190 | 0.360 |
Why?
|
| Abscess | 1 | 2012 | 79 | 0.360 |
Why?
|
| Pacemaker, Artificial | 1 | 2012 | 50 | 0.360 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 66 | 0.360 |
Why?
|
| Organ Preservation | 2 | 2023 | 22 | 0.350 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2005 | 357 | 0.350 |
Why?
|
| Teaching | 1 | 2012 | 165 | 0.340 |
Why?
|
| Sinus of Valsalva | 1 | 2010 | 7 | 0.330 |
Why?
|
| MicroRNAs | 1 | 2017 | 714 | 0.320 |
Why?
|
| Clinical Competence | 4 | 2021 | 731 | 0.320 |
Why?
|
| Transfection | 3 | 2019 | 700 | 0.300 |
Why?
|
| Fluoroquinolones | 2 | 2020 | 33 | 0.300 |
Why?
|
| Quality of Life | 1 | 2017 | 1267 | 0.300 |
Why?
|
| Biomedical Research | 1 | 2012 | 263 | 0.300 |
Why?
|
| Prosthesis Design | 3 | 2021 | 222 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 809 | 0.290 |
Why?
|
| Hemostasis, Surgical | 1 | 2008 | 22 | 0.280 |
Why?
|
| Blood Coagulation Factors | 1 | 2008 | 16 | 0.280 |
Why?
|
| Cell Differentiation | 4 | 2018 | 1391 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2012 | 1665 | 0.280 |
Why?
|
| Postoperative Hemorrhage | 1 | 2008 | 41 | 0.270 |
Why?
|
| Myocytes, Cardiac | 9 | 2005 | 123 | 0.270 |
Why?
|
| United States | 8 | 2026 | 8190 | 0.260 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2016 | 59 | 0.260 |
Why?
|
| Regeneration | 2 | 2005 | 127 | 0.260 |
Why?
|
| Retrospective Studies | 6 | 2017 | 6953 | 0.250 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2017 | 45 | 0.250 |
Why?
|
| Adult | 10 | 2021 | 17567 | 0.240 |
Why?
|
| Extracellular Matrix | 2 | 2018 | 148 | 0.240 |
Why?
|
| Calcium | 3 | 2019 | 587 | 0.240 |
Why?
|
| Stem Cells | 3 | 2020 | 278 | 0.230 |
Why?
|
| Thrombocytopenia | 1 | 2026 | 59 | 0.230 |
Why?
|
| Heparin | 1 | 2026 | 120 | 0.220 |
Why?
|
| Animals | 25 | 2017 | 21489 | 0.210 |
Why?
|
| Postoperative Complications | 3 | 2021 | 1336 | 0.210 |
Why?
|
| Cardiac Catheterization | 3 | 2015 | 293 | 0.210 |
Why?
|
| Ice | 1 | 2023 | 8 | 0.190 |
Why?
|
| Military Medicine | 2 | 2015 | 32 | 0.190 |
Why?
|
| Technology | 1 | 2023 | 53 | 0.190 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2017 | 117 | 0.190 |
Why?
|
| Cell Lineage | 1 | 2004 | 282 | 0.190 |
Why?
|
| Survival Analysis | 3 | 2015 | 579 | 0.190 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 304 | 0.180 |
Why?
|
| Time Factors | 6 | 2012 | 3778 | 0.180 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2022 | 60 | 0.170 |
Why?
|
| Rats | 10 | 2005 | 2005 | 0.170 |
Why?
|
| Vascular Patency | 1 | 2022 | 135 | 0.170 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2015 | 226 | 0.170 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2003 | 154 | 0.170 |
Why?
|
| Ergonomics | 1 | 2021 | 79 | 0.170 |
Why?
|
| Coronary Disease | 4 | 2008 | 246 | 0.170 |
Why?
|
| Myocardial Reperfusion Injury | 3 | 2005 | 29 | 0.160 |
Why?
|
| Dissection | 2 | 2019 | 47 | 0.160 |
Why?
|
| Fatal Outcome | 2 | 2017 | 122 | 0.160 |
Why?
|
| Aspirin | 1 | 2022 | 172 | 0.160 |
Why?
|
| Perioperative Care | 1 | 2021 | 89 | 0.160 |
Why?
|
| Tricuspid Valve | 1 | 2020 | 28 | 0.160 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2016 | 169 | 0.150 |
Why?
|
| Stroke Volume | 1 | 2021 | 345 | 0.150 |
Why?
|
| Educational Measurement | 1 | 2021 | 214 | 0.150 |
Why?
|
| Coronary Circulation | 3 | 2004 | 55 | 0.150 |
Why?
|
| Prognosis | 3 | 2013 | 1792 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 808 | 0.140 |
Why?
|
| Ventricular Function | 2 | 2017 | 22 | 0.140 |
Why?
|
| Glomerular Mesangium | 1 | 1998 | 2 | 0.140 |
Why?
|
| Heart Diseases | 2 | 2011 | 223 | 0.140 |
Why?
|
| Myofibroblasts | 1 | 2018 | 22 | 0.140 |
Why?
|
| Arginine Vasopressin | 1 | 1998 | 20 | 0.140 |
Why?
|
| Contraindications | 1 | 2018 | 52 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2021 | 337 | 0.140 |
Why?
|
| Macrophage-1 Antigen | 1 | 1998 | 29 | 0.140 |
Why?
|
| Epitope Mapping | 1 | 1998 | 52 | 0.140 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 79 | 0.140 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2017 | 66 | 0.140 |
Why?
|
| Disinfectants | 1 | 2018 | 26 | 0.140 |
Why?
|
| Tissue Engineering | 3 | 2004 | 148 | 0.130 |
Why?
|
| Allografts | 1 | 2017 | 47 | 0.130 |
Why?
|
| Thoracotomy | 3 | 2012 | 47 | 0.130 |
Why?
|
| Surgical Instruments | 1 | 2017 | 44 | 0.130 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2017 | 25 | 0.130 |
Why?
|
| Risk Assessment | 4 | 2013 | 2113 | 0.130 |
Why?
|
| GATA4 Transcription Factor | 1 | 2017 | 5 | 0.130 |
Why?
|
| Snails | 1 | 2017 | 6 | 0.130 |
Why?
|
| Arginine | 1 | 1998 | 136 | 0.130 |
Why?
|
| Cell Communication | 1 | 1998 | 135 | 0.130 |
Why?
|
| Length of Stay | 1 | 2021 | 828 | 0.130 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 78 | 0.130 |
Why?
|
| Muscle, Smooth | 1 | 2018 | 135 | 0.130 |
Why?
|
| Cytokines | 2 | 2020 | 964 | 0.130 |
Why?
|
| Povidone-Iodine | 1 | 2017 | 5 | 0.130 |
Why?
|
| Pseudomonas Infections | 1 | 2017 | 73 | 0.130 |
Why?
|
| Coronary Thrombosis | 1 | 2017 | 21 | 0.130 |
Why?
|
| Lung | 2 | 2017 | 969 | 0.120 |
Why?
|
| Fibrosis | 1 | 2017 | 172 | 0.120 |
Why?
|
| Caspase 3 | 3 | 2005 | 108 | 0.120 |
Why?
|
| Surgical Flaps | 1 | 2017 | 117 | 0.120 |
Why?
|
| Mast Cells | 1 | 2016 | 51 | 0.120 |
Why?
|
| Spinal Cord | 1 | 2017 | 210 | 0.120 |
Why?
|
| Urinary Tract | 1 | 2016 | 11 | 0.120 |
Why?
|
| Urinary Catheterization | 1 | 2016 | 20 | 0.120 |
Why?
|
| Cells, Cultured | 6 | 2004 | 2194 | 0.120 |
Why?
|
| Silicones | 1 | 2015 | 14 | 0.120 |
Why?
|
| Staphylococcus aureus | 1 | 2017 | 183 | 0.110 |
Why?
|
| Urinary Retention | 1 | 2016 | 29 | 0.110 |
Why?
|
| Registries | 2 | 2016 | 934 | 0.110 |
Why?
|
| Polyesters | 1 | 2015 | 45 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 211 | 0.110 |
Why?
|
| Motor Skills | 2 | 2012 | 61 | 0.110 |
Why?
|
| Transplantation, Homologous | 6 | 2005 | 250 | 0.110 |
Why?
|
| Neutrophils | 1 | 1998 | 396 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 88 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 297 | 0.110 |
Why?
|
| Stents | 1 | 2019 | 501 | 0.110 |
Why?
|
| Disease Management | 1 | 2016 | 235 | 0.110 |
Why?
|
| Device Removal | 2 | 2012 | 64 | 0.110 |
Why?
|
| Mice, Transgenic | 4 | 2005 | 1291 | 0.110 |
Why?
|
| Mice | 10 | 2005 | 11185 | 0.110 |
Why?
|
| China | 1 | 2015 | 181 | 0.110 |
Why?
|
| Apoptosis | 5 | 2005 | 1100 | 0.100 |
Why?
|
| Obesity, Morbid | 1 | 2015 | 95 | 0.100 |
Why?
|
| California | 1 | 2014 | 178 | 0.100 |
Why?
|
| Vascular Resistance | 2 | 2004 | 47 | 0.100 |
Why?
|
| Collagen | 2 | 2004 | 135 | 0.100 |
Why?
|
| Severity of Illness Index | 3 | 2013 | 1568 | 0.090 |
Why?
|
| Diverticulum | 1 | 2012 | 12 | 0.090 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2012 | 33 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 375 | 0.090 |
Why?
|
| Deglutition Disorders | 1 | 2012 | 44 | 0.090 |
Why?
|
| Biocompatible Materials | 2 | 2003 | 154 | 0.090 |
Why?
|
| Task Performance and Analysis | 1 | 2012 | 130 | 0.090 |
Why?
|
| Suture Techniques | 1 | 2012 | 97 | 0.090 |
Why?
|
| Aneurysm | 1 | 2012 | 58 | 0.090 |
Why?
|
| Drainage | 1 | 2012 | 153 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2015 | 5681 | 0.090 |
Why?
|
| Choristoma | 1 | 2011 | 23 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2019 | 3339 | 0.090 |
Why?
|
| Wound Healing | 1 | 2012 | 193 | 0.090 |
Why?
|
| Rats, Inbred ACI | 3 | 2005 | 6 | 0.090 |
Why?
|
| History, 19th Century | 1 | 2011 | 40 | 0.080 |
Why?
|
| Behcet Syndrome | 1 | 2011 | 4 | 0.080 |
Why?
|
| Coronary Aneurysm | 1 | 2011 | 7 | 0.080 |
Why?
|
| Varicose Veins | 1 | 2011 | 7 | 0.080 |
Why?
|
| Cell Movement | 3 | 2004 | 484 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 319 | 0.080 |
Why?
|
| American Heart Association | 2 | 2022 | 130 | 0.080 |
Why?
|
| Learning | 1 | 2012 | 186 | 0.080 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2010 | 7 | 0.080 |
Why?
|
| Education, Medical | 1 | 2012 | 183 | 0.080 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2011 | 62 | 0.080 |
Why?
|
| Algorithms | 1 | 2015 | 1060 | 0.080 |
Why?
|
| Computer-Assisted Instruction | 1 | 2011 | 80 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 312 | 0.080 |
Why?
|
| Gene Expression | 3 | 2005 | 855 | 0.070 |
Why?
|
| Mutation | 1 | 2018 | 2674 | 0.070 |
Why?
|
| Pneumonectomy | 1 | 2011 | 131 | 0.070 |
Why?
|
| Disease Models, Animal | 4 | 2005 | 2329 | 0.070 |
Why?
|
| Superoxide Dismutase | 3 | 2005 | 223 | 0.070 |
Why?
|
| Cyclic AMP | 2 | 2003 | 144 | 0.070 |
Why?
|
| General Surgery | 1 | 2011 | 210 | 0.070 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2008 | 35 | 0.070 |
Why?
|
| Curriculum | 1 | 2012 | 609 | 0.070 |
Why?
|
| Computer Simulation | 1 | 2011 | 488 | 0.070 |
Why?
|
| Multiple Organ Failure | 1 | 2008 | 48 | 0.070 |
Why?
|
| Risk Factors | 2 | 2026 | 5471 | 0.070 |
Why?
|
| Dyspnea | 1 | 2008 | 120 | 0.070 |
Why?
|
| Models, Animal | 2 | 2005 | 242 | 0.070 |
Why?
|
| Cardiotonic Agents | 2 | 2004 | 54 | 0.070 |
Why?
|
| Graft Survival | 2 | 2005 | 300 | 0.060 |
Why?
|
| Pregnancy | 1 | 2014 | 2402 | 0.060 |
Why?
|
| Thermodilution | 2 | 2003 | 2 | 0.060 |
Why?
|
| Cognition | 1 | 2011 | 514 | 0.060 |
Why?
|
| Liver | 1 | 2011 | 875 | 0.060 |
Why?
|
| Microcirculation | 2 | 2004 | 59 | 0.060 |
Why?
|
| Respiratory Insufficiency | 1 | 2008 | 155 | 0.060 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2004 | 54 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2005 | 15 | 0.060 |
Why?
|
| Chimera | 1 | 2005 | 44 | 0.060 |
Why?
|
| Cell Culture Techniques | 2 | 2004 | 195 | 0.060 |
Why?
|
| Cold Ischemia | 1 | 2005 | 3 | 0.060 |
Why?
|
| Genes, bcl-2 | 1 | 2005 | 10 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 140 | 0.060 |
Why?
|
| Cardiac Myosins | 1 | 2005 | 25 | 0.060 |
Why?
|
| Cyclosporine | 1 | 2005 | 77 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 4 | 2005 | 3504 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 185 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 2790 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 32 | 0.050 |
Why?
|
| Butyrates | 1 | 2004 | 16 | 0.050 |
Why?
|
| Bioartificial Organs | 1 | 2004 | 1 | 0.050 |
Why?
|
| Intercellular Junctions | 1 | 2004 | 8 | 0.050 |
Why?
|
| Cell Fusion | 1 | 2004 | 39 | 0.050 |
Why?
|
| Organometallic Compounds | 1 | 2004 | 71 | 0.050 |
Why?
|
| Patient Selection | 1 | 2007 | 484 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 104 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2011 | 995 | 0.050 |
Why?
|
| Granulocytes | 1 | 2004 | 73 | 0.050 |
Why?
|
| Cell Transplantation | 1 | 2004 | 41 | 0.050 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2004 | 67 | 0.050 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2003 | 3 | 0.050 |
Why?
|
| Pulmonary Circulation | 1 | 2003 | 27 | 0.050 |
Why?
|
| Colforsin | 1 | 2003 | 25 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2004 | 83 | 0.050 |
Why?
|
| Phenols | 1 | 2004 | 77 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2005 | 593 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2004 | 257 | 0.050 |
Why?
|
| Reperfusion | 1 | 2003 | 38 | 0.050 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2003 | 30 | 0.050 |
Why?
|
| Autoimmunity | 1 | 2005 | 250 | 0.050 |
Why?
|
| Perfusion | 1 | 2003 | 83 | 0.050 |
Why?
|
| Embryo, Mammalian | 1 | 2004 | 158 | 0.050 |
Why?
|
| Lung Transplantation | 1 | 2003 | 75 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 382 | 0.050 |
Why?
|
| Survival Rate | 1 | 2005 | 847 | 0.050 |
Why?
|
| Swine | 4 | 2004 | 398 | 0.050 |
Why?
|
| Cell Adhesion | 2 | 2004 | 218 | 0.050 |
Why?
|
| Antioxidants | 1 | 2004 | 252 | 0.050 |
Why?
|
| Growth Substances | 1 | 2002 | 34 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 22 | 0.040 |
Why?
|
| Lymphokines | 1 | 2002 | 67 | 0.040 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2002 | 46 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2003 | 626 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 157 | 0.040 |
Why?
|
| Rats, Inbred Strains | 3 | 2005 | 150 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 1012 | 0.040 |
Why?
|
| Coronary Angiography | 2 | 2011 | 212 | 0.040 |
Why?
|
| Acute Disease | 1 | 2021 | 664 | 0.040 |
Why?
|
| Spermidine | 1 | 1998 | 1 | 0.040 |
Why?
|
| Spermine | 1 | 1998 | 3 | 0.040 |
Why?
|
| omega-N-Methylarginine | 1 | 1998 | 8 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2011 | 2496 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 1998 | 97 | 0.030 |
Why?
|
| Guanidine | 1 | 1998 | 24 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2005 | 605 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 1998 | 414 | 0.030 |
Why?
|
| New York | 1 | 2015 | 144 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 692 | 0.030 |
Why?
|
| Transplantation, Heterotopic | 2 | 2005 | 6 | 0.030 |
Why?
|
| Chemokine CCL2 | 2 | 2005 | 61 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 106 | 0.030 |
Why?
|
| Mortality | 1 | 2015 | 162 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 4878 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2004 | 15 | 0.030 |
Why?
|
| Papaverine | 2 | 2004 | 7 | 0.030 |
Why?
|
| Myocardial Contraction | 2 | 2004 | 88 | 0.030 |
Why?
|
| Caspases | 2 | 2005 | 176 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 1998 | 875 | 0.020 |
Why?
|
| Peroxidase | 2 | 2004 | 70 | 0.020 |
Why?
|
| Blood Flow Velocity | 2 | 2003 | 79 | 0.020 |
Why?
|
| Septal Occluder Device | 1 | 2013 | 11 | 0.020 |
Why?
|
| Inflammation | 3 | 2004 | 1198 | 0.020 |
Why?
|
| Cell Division | 2 | 2004 | 451 | 0.020 |
Why?
|
| Vocal Cord Paralysis | 1 | 2012 | 10 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 859 | 0.020 |
Why?
|
| Subclavian Artery | 1 | 2012 | 26 | 0.020 |
Why?
|
| Rats, Wistar | 2 | 2004 | 184 | 0.020 |
Why?
|
| Linear Models | 2 | 2003 | 405 | 0.020 |
Why?
|
| Disease Progression | 2 | 2008 | 1229 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2004 | 869 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2012 | 45 | 0.020 |
Why?
|
| Angiography | 1 | 2012 | 154 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2004 | 899 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 2324 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 665 | 0.020 |
Why?
|
| Ligation | 1 | 2011 | 37 | 0.020 |
Why?
|
| Thoracoscopes | 1 | 2011 | 2 | 0.020 |
Why?
|
| Surgical Staplers | 1 | 2011 | 6 | 0.020 |
Why?
|
| Computer Graphics | 1 | 2011 | 19 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2012 | 293 | 0.020 |
Why?
|
| Blood Pressure | 2 | 2003 | 537 | 0.020 |
Why?
|
| Endoscopy | 1 | 2011 | 92 | 0.020 |
Why?
|
| Patient Positioning | 1 | 2011 | 52 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2003 | 1117 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2014 | 881 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2011 | 196 | 0.020 |
Why?
|
| Phenotype | 2 | 2004 | 1236 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 202 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2004 | 503 | 0.020 |
Why?
|
| Echocardiography | 1 | 2011 | 513 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 715 | 0.020 |
Why?
|
| Transcription Factors | 1 | 1994 | 1561 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 47 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 2005 | 84 | 0.010 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2005 | 40 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2005 | 111 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2005 | 154 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 2005 | 119 | 0.010 |
Why?
|
| Superoxides | 1 | 2004 | 73 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2004 | 40 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2004 | 21 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 449 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2005 | 187 | 0.010 |
Why?
|
| Collateral Circulation | 1 | 2004 | 28 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2004 | 95 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2005 | 143 | 0.010 |
Why?
|
| Pericardium | 1 | 2004 | 35 | 0.010 |
Why?
|
| Tensile Strength | 1 | 2004 | 32 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2004 | 53 | 0.010 |
Why?
|
| Epinephrine | 1 | 2004 | 46 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 2004 | 70 | 0.010 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2004 | 29 | 0.010 |
Why?
|
| Hyperemia | 1 | 2003 | 14 | 0.010 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2004 | 148 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 2003 | 29 | 0.010 |
Why?
|
| Lung Compliance | 1 | 2003 | 5 | 0.010 |
Why?
|
| Microspheres | 1 | 2003 | 56 | 0.010 |
Why?
|
| Extravascular Lung Water | 1 | 2003 | 3 | 0.010 |
Why?
|
| Partial Pressure | 1 | 2003 | 9 | 0.010 |
Why?
|
| Cell Polarity | 1 | 2004 | 110 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2004 | 241 | 0.010 |
Why?
|
| E-Selectin | 1 | 2003 | 19 | 0.010 |
Why?
|
| Immunity | 1 | 2004 | 107 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 108 | 0.010 |
Why?
|
| Monitoring, Intraoperative | 1 | 2003 | 47 | 0.010 |
Why?
|
| Respiratory System | 1 | 2003 | 46 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2003 | 130 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2004 | 180 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2004 | 240 | 0.010 |
Why?
|
| Surface Properties | 1 | 2004 | 283 | 0.010 |
Why?
|
| Monocytes | 1 | 2005 | 362 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 195 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2004 | 436 | 0.010 |
Why?
|
| Actins | 1 | 2004 | 265 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2004 | 372 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 401 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 180 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 377 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 542 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 22 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2003 | 253 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 324 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2002 | 111 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 2003 | 124 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 709 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2002 | 117 | 0.010 |
Why?
|
| Oxygen | 1 | 2003 | 323 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 667 | 0.010 |
Why?
|
| Extremities | 1 | 2002 | 63 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2002 | 234 | 0.010 |
Why?
|
| Ischemia | 1 | 2002 | 203 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 1720 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2004 | 929 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 1583 | 0.010 |
Why?
|
| Leucine Zippers | 1 | 1994 | 12 | 0.010 |
Why?
|
| Activating Transcription Factor 3 | 1 | 1994 | 7 | 0.010 |
Why?
|
| Enkephalins | 1 | 1994 | 20 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 1994 | 34 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1994 | 142 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1994 | 84 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1994 | 85 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1994 | 54 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1994 | 162 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1994 | 426 | 0.010 |
Why?
|
| Base Sequence | 1 | 1994 | 1332 | 0.010 |
Why?
|
| Binding Sites | 1 | 1994 | 921 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1994 | 963 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 1980 | 0.000 |
Why?
|
| DNA | 1 | 1994 | 853 | 0.000 |
Why?
|
| Signal Transduction | 1 | 1994 | 3168 | 0.000 |
Why?
|